CDH5

Across TCGA pan-cancer cohorts, CDH5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDH5 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDH5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDH5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CDH5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.841	1.000	.008	21	view →
HNSC	DFS	Median	II,III,IV	0.909	0.982	.006	9	view →
CCRCC	DFS	Tertile	III,IV	0.692	0.384	.023	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
GBM	OS	Quartile	All	0.627	0.454	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDH5–LUAD (OS)

Open the LUAD breakdown →